Remarkable developments in the systemic treatment of advanced non–small-cell lung
cancer have taken place in the past few years. Targeted therapies have been largely …

Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular
epidermal growth factor binding domain and an intracellular tyrosine kinase domain that …

Among the most promising agents in clinical development to treat non-small-cell lung cancer
(NSCLC) are the epidermal growth factor receptor (EGFR) targeting agents. A series of …

Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer
(NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of …

Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Gefitinib (Iressa™) is a synthetic anilinoquinazoline capable of inhibiting the epidermal
growth factor receptor tyrosine kinase in vitro at nanomolar concentrations. In phase I trials …

Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …

Purpose: Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth
factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …